Home / Learn / Precision Medicine / Treatment / Immunotherapy / Immune-Related Adverse Events

Immune-Related Adverse Events

The Latest Resources

Members of the ACCC IO Institute Executive Committee discuss the importance of standardizing education for Immunotherapy patients and how designating a champion within your practice can play a critical role in the success of irAE identification and management.(features Sanjiv Agarwala, MD; and Niesha Griffith, MS, RPH, FASHP)

 
  • irAE Workup Guidelines

    Many organizations have published formal recommendations, or workup guidelines, for managing irAEs, including ASCO, ESMO, NCCN, and SITC.The following can be used as a directory for the current irAE workup guidelines.

  • Subspecialty Insights in Immuno-Oncology: A Closer Look at APPs
    By Sarah Sagorsky, MPAS, PA-C

    Advanced Practice Providers (APPs), such as nurse practitioners and physician assistants, play a fundamental role within medical oncology departments and the care of patients with cancer.

  • Managing Dermatologic Adverse Events From Immunotherapy
    By Joshua Arbesman, MD

    Oncodermatology is a rapidly developing field that is attracting significant interest and generating new literature in the context of cancer treatment strategies.

  • Emergency Medicine Providers: Key Partners in the Acute Care of irAEs
    By Jason Bischof, MD

    The non-specific adverse events of immune-based therapies, which often mimic autoimmune disorders rather than traditional cytotoxic effects, pose a significant challenge to emergency medicine providers.

From Oncology Issues

Toxicity Team Article
 

Blog Posts

FROM THE ACCCBUZZ BLOG

  • Precision Medicine Packs a Punch: Antibody-Drug Conjugates for Non-Small Cell Lung Cancer
    Nicole A. Colwell, MD
    March 31, 2025
    While ADCs have emerged as a promising development for patients with NSCLC, they present unique challenges in clinical practice, such as optimal patient selection, treatment sequencing, and toxicity management. ADCs can also elicit significant adverse events, particularly when combined with immunotherapy, raising concerns about overlapping toxicities and the need for close monitoring for treatment-related complications.
  • Early Identification and Management of Pneumonitis and Other irAEs in Patients with NSCLC
    By Sarah Sagorsky, MPAS, PA-C
    September 01, 2023
    As immune checkpoint inhibitors have become the standard of care for eligible patients with NSCLC, frequent monitoring of irAEs as well as provider and patient education on the signs and symptoms of pneumonitis can ensure improved clinical outcomes for patients.
  • A New Decade for Advancements in Immunotherapy
    June 08, 2023
    June is Cancer Immunotherapy Month, and ACCC is highlighting the important work that it and its partners are doing to increase patient access to these novel therapies.
  • Sigrun Hallmeyer pic
    June Is Cancer Immunotherapy Month
    June 25, 2020
    In recognition of Cancer Immunotherapy Month, ACCCBuzz talked to Sigrun Hallmeyer, MD, the chair of the ACCC Immuno-Oncology Institute’s Executive Committee.

On-Demand Webinars

  • Learn how the microbiome could potentially be used to predict and enhance response to I-O therapy and to recognize patients who could be at risk for developing immune-related adverse events.